Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Fed. Court Says Medicare Must Cover Off-Label
Prescriptions
In Layzer v. Leavitt, 07 Civ. 11339 (HB), NYLJ 1202485563289, at *1 (SDNY, Decided March 7, 2011), the U.S. Court of Appeals for the Southern District of New York recently concluded that the Department of Health and Human Services must cover the costs of prescription medications prescribed “off label.” The case involved two patients, one prescribed Cetrotide to treat a rare form of ovarian cancer and the other prescribed Increlex to treat a rare and degenerative form of muscular dystrophy. Their Medicare Part D plan sponsors denied coverage for the drugs because they had not been approved by the Food and Drug Administration (FDA) for treatment of the two patients' conditions. On appeal, a Medicare Part D Independent Review Entity affirmed the denials, concluding that the plan sponsors were not required to provide coverage because the drugs were not being used for a medically accepted indication. The appeals authority explained that “a medically accepted indication means a use that is approved by the FDA or a use that is supported by one or more citations in ' drug compendia.” (The compendia are: 1) the American Hospital Formulary Service Drug Information; 2) the United States Pharmacopeia-Drug Information; and 3) the DRUGDEX Information System. 42 U.S.C. ' 1396r-8(g)(1)(B)(i).) When the plaintiffs sought final review of the Health and Human Services secretary's denial of reimbursement under 42 USC ' 405(g), the federal court reversed and ordered coverage. It found that the definition of a “covered part D drug” in the Social Security Act, 42 USC ' 1395 et seq., did not impose the so-called compendia requirement.
IV-Administered Nutrition Kills Several Hospital
Patients in AL
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
Defining commercial real estate asset class is essentially a property explaining how it identifies — not necessarily what its original intention was or what others think it ought to be. This article discusses, from a general issue-spot and contextual analysis perspective, how lawyers ought to think about specialized leasing formats and the regulatory backdrops that may inform what the documentation needs to contain for compliance purposes.
As courts and discovery experts debate whether hyperlinked content should be treated the same as traditional attachments, legal practitioners are grappling with the technical and legal complexities of collecting, analyzing and reviewing these documents in real-world cases.
How to Convey Your Merits In a Way That Earns Trust, Clients and Distinctions Just as no two individuals have the exact same face, no two lawyers practice in their respective fields or serve clients in the exact same way. Think of this as a "Unique Value Proposition." Internal consideration about what you uniquely bring to your clients, colleagues, firm and industry can provide untold benefits for your law practice.
The ever-evolving digital marketing landscape, coupled with the industry-wide adoption of programmatic advertising, poses a significant threat to the effectiveness and integrity of digital advertising campaigns. This article explores various risks to digital advertising from pixel stuffing and ad stacking to domain spoofing and bots. It will also explore what should be done to ensure ad fraud protection and improve effectiveness.
This article offers practical insights and best practices to navigate the path from roadmap to rainmaking, ensuring your business development efforts are not just sporadic bursts of activity, but an integrated part of your daily success.